A detailed history of Ensign Peak Advisors, Inc transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 164,944 shares of SWTX stock, worth $5.87 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
164,944
Previous 164,744 0.12%
Holding current value
$5.87 Million
Previous $6.21 Million 14.84%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$32.04 - $42.76 $6,408 - $8,552
200 Added 0.12%
164,944 $5.28 Million
Q2 2024

Aug 13, 2024

BUY
$36.06 - $47.62 $2.27 Million - $3 Million
62,953 Added 61.85%
164,744 $6.21 Million
Q1 2024

May 14, 2024

BUY
$36.5 - $52.5 $2.99 Million - $4.29 Million
81,791 Added 408.96%
101,791 $5.01 Million
Q4 2023

Feb 14, 2024

BUY
$18.94 - $37.24 $378,800 - $744,800
20,000 New
20,000 $730,000
Q3 2022

Nov 14, 2022

SELL
$24.1 - $39.66 $1.7 Million - $2.8 Million
-70,499 Reduced 93.11%
5,220 $149,000
Q2 2022

Aug 12, 2022

SELL
$18.36 - $60.07 $706,327 - $2.31 Million
-38,471 Reduced 33.69%
75,719 $1.87 Million
Q1 2022

May 16, 2022

BUY
$48.97 - $65.46 $558,747 - $746,898
11,410 Added 11.1%
114,190 $6.45 Million
Q4 2021

Feb 11, 2022

BUY
$53.3 - $75.84 $1.1 Million - $1.56 Million
20,619 Added 25.1%
102,780 $6.37 Million
Q3 2021

Nov 12, 2021

BUY
$62.66 - $88.26 $1.1 Million - $1.55 Million
17,527 Added 27.12%
82,161 $5.21 Million
Q2 2021

Aug 13, 2021

BUY
$67.45 - $85.63 $1.38 Million - $1.75 Million
20,408 Added 46.14%
64,634 $5.33 Million
Q1 2021

May 12, 2021

BUY
$65.1 - $93.59 $1.18 Million - $1.7 Million
18,200 Added 69.93%
44,226 $3.25 Million
Q3 2020

Nov 12, 2020

BUY
$36.14 - $51.99 $600,755 - $864,229
16,623 Added 176.78%
26,026 $1.24 Million
Q1 2020

May 11, 2020

BUY
$20.44 - $41.21 $192,197 - $387,497
9,403 New
9,403 $254,000

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.22B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.